Literature DB >> 16239907

IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma.

W J Chng, A Gualberto, R Fonseca.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16239907     DOI： 10.1038/sj.leu.2403997

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  23 in total

1.  Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.

Authors:  M A Frassanito; K De Veirman; V Desantis; L Di Marzo; D Vergara; S Ruggieri; T Annese; B Nico; E Menu; I Catacchio; R Ria; V Racanelli; M Maffia; E Angelucci; D Derudas; R Fumarulo; F Dammacco; D Ribatti; K Vanderkerken; A Vacca
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

Review 2.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-11-07       Impact factor: 5.922

Review 3.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-01-27       Impact factor: 5.922

4.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

5.  Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

Authors:  A C Sprynski; D Hose; A Kassambara; L Vincent; M Jourdan; J F Rossi; H Goldschmidt; B Klein
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

6.  Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.

Authors:  DeannaLee M Beauvais; Oisun Jung; Yang Yang; Ralph D Sanderson; Alan C Rapraeger
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

7.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

8.  Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma.

Authors:  C A Pappa; G Tsirakis; F E Psarakis; A Kolovou; M Tsigaridaki; D Stafylaki; K Sfiridaki; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-12-25       Impact factor: 3.064

9.  Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Authors:  D Chiron; S Maïga; S Surget; G Descamps; P Gomez-Bougie; S Traore; N Robillard; P Moreau; S Le Gouill; R Bataille; M Amiot; C Pellat-Deceunynck
Journal:  Blood Cancer J       Date:  2013-06-07       Impact factor: 11.037

10.  DNA methylation in multiple myeloma is weakly associated with gene transcription.

Authors:  Sungwon Jung; Seungchan Kim; Molly Gale; Irene Cherni; Rafael Fonseca; John Carpten; Bodour Salhia
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.